Phase I trial of MGN 1404, TNF-alpha expressing MIDGE-vector non-viral gene transfer, in patients with malignant melanoma.
Phase of Trial: Phase I
Latest Information Update: 21 Oct 2013
At a glance
- Drugs MGN 1404 (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 21 Oct 2013 Status changed from not yet recruiting to recruiting, according to a Mologen media release.
- 15 Apr 2013 Approval has been granted by the Paul-Ehrlich Institute, according to a Mologen media release.
- 02 Jul 2012 New trial record